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Abstract
The incidence of most cancers increases with age, especially from middle age 
onward, so today cancer can be considered an age-related disease. One of the keys 
to healthy and successful aging is reducing the advent of serious disabilities caused 
by diseases related to aging. One of the cornerstones of anti-aging is hormone 
replacement therapy to treat age-related diseases caused by sex hormone deficiency 
in women. However, there are many studies that question the relationship between 
hormone replacement therapies with cancer recurrence. Hormone replacement 
therapy (HRT) has the potential to affect both quality of life and survival in 
menopausal women. Although data in the literature is controversial, many clini-
cians remain reluctant to write HRT for gynecologic cancer patients due to fear of 
relapse but HRT does not appear to be associated with an increased risk of relapse in 
ovarian and endometrial cancer survivors, especially when used for a short period 
of time.
Keywords: endometrial cancer, gynecologic cancers, hormone replacement therapy, 
ovarian cancer, cervical cancer
1. Introduction
Menopause is defined by the World Health Organization (WHO) as the 
complete disappearance of cyclic menstruation over a period of 12 months due 
to a reduction in the production of estrogen and progesterone hormones from a 
woman’s ovaries [1]. Menopause can be defined by more concrete values in labora-
tory tests. According to the findings of amenorrhea and hypestrogenemia stud-
ies, serum FSH levels above 40 IU/L were defined. Subjectively, menopause can 
also be diagnosed by vasomotor symptoms, such as hot flashes. The permanent 
cessation of menstrual periods can occur naturally or can be induced by surgery, 
chemotherapy or radiation, leading to estrogen deficiency and loss of reproduc-
tive function [2]. Symptoms are more pronounced with a sudden drop in circulat-
ing estrogen levels. These symptoms are severe in premature ovarian failure and 
surgical menopause. Natural menopause is often seen between the ages of 45 and 
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55, but its onset varies from woman to woman. The average age of natural meno-
pause in our country (Turkey) is 47 [3].
A menopausal statement can disrupt a woman’s personal and social life. 
Vasomotor symptoms (e.g., hot flashes and night sweats) are the most common 
symptoms and can be treated very effectively with estrogen-based hormone 
therapy. The decision to use estrogen (usually only hormone therapy or hormone 
replacement therapy or HT) treatment involves balancing potential benefits with 
potential risks. A woman who desires HRT and has an intact uterus must also 
receive progestogen with the estrogen to protect her uterus from endometrial 
hyperplasia or malignancy. It is assumed that if a woman has had a hysterectomy 
that she no longer needs a progestin. However, progesterone is different, as it can 
provide symptom relief from sleep disturbance and mood instability, and there is 
increasing evidence to support its offering protection to breast tissue [4].
The relationship between early surgical menopause and poor cognitive out-
comes has been demonstrated. Increased risk of cognitive impairment especially in 
patients undergoing oophorectomy at a young age revealed that this relationship is 
age-related [5].
Furthermore, cancer treatment often accelerates menopause and then affects 
quality of life. Postmenopausal women are at increased risk for vaginal dryness, 
dyspareunia, urogenital atrophy and sexual dysfunction. Hormone replacement 
therapy (HRT) has been proven to be highly effective in alleviating menopausal 
symptoms, such as hot flashes, night sweats, dyspareunia, sexual disorders and 
insomnia, as well as preventing osteoporosis. Life satisfaction and social function-
ing can be improved by overcoming menopausal symptoms and increasing resis-
tance to age-related pathologies.
The number of menopausal women will also increase as the population ages. 
Accurate estimation of the postmenopausal population is an important point for 
health care providers to consider, as the incidence of all cancers increases with 
aging. If life satisfaction, social functioning and psychological resources are 
enhanced by increasing resistance to against age-related pathologies, the experience 
of aging can be improved.
To clarify the possible effective management of menopausal symptoms, the 
main evidence in the literature was analyzed to investigate the role of hormone 
replacement therapy in patients affected by endometrial, ovarian or cervical cancer.
2. Endometrial cancer
A number of clinical trials have reported that HRT does not increase the risk 
of recurrence of endometrial cancer (EC) even after treatment [6, 7]. In contrast, 
studies’ showing that estrogen exposure is associated with an increase in mitosis of 
endometrial cells, placing them in a specific molecular configuration sensitive to 
DNA damage [8].
The most common gynecological cancer, endometrial cancer is seen in the 
postmenopausal period, but 25% of diagnosed patients are premenopausal with 
approximately 2.5–14.4% of the patients less than 40 years old [9].
As a result, a large number of women will be exposed to the sudden iatrogenic 
onset of postmenopausal morbidity, consisting of standard abdominal hysterec-
tomy and bilateral oophorectomy procedures. In addition, surgery-induced meno-
pausal symptoms tend to be more severe than those caused by normal menopause, 
and in these patients, surgery is usually followed by chemotherapy or radiotherapy 
[10]. Since EC is typically diagnosed with a good prognosis in the early stage of the 
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disease, relieving these symptoms is an important issue in terms of quality of life 
after treatment [11].
The endometrioid EC type is associated with estrogen exposure and endometrial 
hyperplasia. The role of estrogens in providing relapse after hysterectomy for EC 
is less clear and controversial. Since it does not increase recurrence, there are a 
number of current clinical studies that report HRT should be considered even after 
EC therapy [12]. For relief of menopause-related vasomotor symptoms (VMS), 
systemic usage of HRT with either (1) conventional estrogens/progestogens or (2) 
conjugated estrogens/bazedoxifene is the most effective regime. Currently, method 
2 conjugated estrogens, with a selective estrogen receptor modulator such as 
bazedoxifene, is a very popular replacement of progestin. This method is useful for 
protection of the endometrium.
Although these finding were based on retrospective or cohort controlled study 
results, HRT use does not seem to increase the risk of EC recurrence. Creasman 
et al. reported a retrospective study of 47 cases of stage I endometrial cancer 
patients treated with via the oral or vaginal route using conjugated estrogen (0.625 
or 1.25 mg/dl). HRT was initiated within 15 months (range 0–81 months) of the 
median interval after cancer treatment and patients were followed up for 32 months 
(range 6–84 months) after the onset of HRT. In the control group, 174 patients 
who began treatment at the same time were compared. No difference was observed 
between the groups in terms of prognostic aspects. Only one recurrence (2.1%) was 
observed in the estrogen-treated group and 26 recurrences (14.9%) were observed 
in the control group. The recurrent patient in the HRT group had been treated 
with estrogen only for 3 months and had discontinued HRT use 18 months before 
relapse. Disease-free survival (DFS) and overall survival (OS) were significantly 
longer in the estrogen-treated group [13].
A retrospective paired cohort study was conducted with 75 women being treated 
for stages I–III EC who received an average of 83 months of HRT (conjugated equine 
estrogen-oral, 0.625 mg/dl with or without medroxyprogesterone acetate-oral, 
2.5 mg/dl). These women were then compared with matched controls who received 
an average of 69 months of treatment. The study revealed lower recurrence rate (1 
vs. 14% in the control group) and significantly longer DFS (P = 0.006) in the HRT 
group [14].
A total of 50 patients with stage I or stage II EC who had combined HRT 
(0.625 mg conjugated equine estrogen plus continuous oral daily regimen and 
2.5 mg medroxyprogesterone acetate) of 4–8 weeks postoperatively were compared 
to 52 patients for control purposes. In the first prospective paired cohort study, no 
recurrence was observed in the HRT group but a relapse was observed in the control 
group [12].
A retrospective case-control study was conducted with 44 clinical stage I 
patients (defined as grade 1 or 2 tumors), using oral estrogens (0.625 or 1.25 mg/dl) 
with or without combined progesterone. The study revealed no metastases to lymph 
nodes or other organs [15].
Serous papillary and clear cell carcinomas, which are mostly seen in postmeno-
pausal women and constitute approximately 8% of all ECs, have poor prognosis 
even if they are caught at an early stage. Since they do not have estrogen and 
progesterone receptors, it is not thought that they are not stimulated when HRT is 
used after surgical treatment. A safe recommendation cannot be raised because no 
study has addressed the use of HRT after treatment in all of the above histological 
subtypes of EC. As for uterine sarcomas, endometrial stromal sarcomas are consid-
ered estrogen-dependent because they express estrogen and progesterone receptors, 
and the application of HRT in these sarcomas should be avoided [16].
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Although it is mainly based on retrospective, case or cohort controlled studies 
based on various biases, the use of HRT, in women with stage I and/or II EC, the risk 
of relapse was demonstrated with data that did not increase. Selecting healthier and 
younger women to explain the protective effect of HRT on recurrence in survivors 
of EC may eliminate this publication bias.
Although it is based on retrospective or cohort-controlled studies, nowadays, a 
number of clinical studies have reported that HRT should be considered even after 
treatment of endometrial cancer (EC) without increasing the risk of recurrence [17].
Although the results related to EC do not completely exclude the possibility of 
increasing the risk of recurrence, they argue that HRT does not matter the mag-
nitude of such a risk. The positive effect of HRT on quality of life outweighs the 
unfounded risk of recurrence. Additional well-designed RCTs are needed for the 
definite recommendations including the factors that may be related to recurrence 
such as characteristics and treatment of cancer, different types of HRT, the disease-
free interval before the onset of HRT, and the duration of HRT use. To determine 
the best therapeutic option between new hormones and non-hormonal regimens 
every EC survivor dealing with HRT must be informed of the available data and 
analyzed in a personalized way.
3. Ovarian cancer
Worldwide, among patients diagnosed with gynecological malignancies, ovarian 
cancer is the leading cause of death. Most women affected are postmenopausal, but 
some are younger. Menopausal symptoms in the iatrogenic group are generally more 
pronounced than those following naturally occurring menopause and affect quality 
of life and health outcomes [18, 19].
After the treatment of a serious disease such as ovarian cancer, more attention 
should be paid to the women’s quality of life. Presently, the WHO, Europe, and the 
United States (US) have guidelines on hormone therapy that do not mention ovar-
ian cancer and conclude that evidence for the increased risk of cancer due to HRT is 
in sufficient to make a definite recommendation. According to the guidelines in the 
United Kingdom (UK), such risk is only increased by prolonged use. In the case of 
epithelial ovarian cancer, the World Health Organization, European and US guide-
lines on hormone therapy suggest, that evidence for increased risk of relapse due to 
HRT is in sufficient to make a definite suggestion, but the rules in the UK indicate 
increased risk for long-term users [20].
There is insufficient data on the effect of HRT usage period on the onset and 
progression of ovarian cancer. The effect of some known prognostic factors, such 
as residual tumor and tumor differentiation during diagnosis, are more important 
than the duration of HRT use [21]. Despite these results, it is very likely that the 
heterogeneity of samples, including factors of age, stages and classifications, differ-
ent treatment modalities (chemotherapy, surgery alone, radiotherapy or both) and 
different follow-up times, will reflect the selection bias [22].
As we know, estrogen replacement therapy (ERT) is safe in patients who have 
undergone surgically induced menopause by the removal of the uterus and bilateral 
ovaries. In order to prevent the stimulating effect of estrogen on normal and hyper-
plasic endometrium, several studies have added progesterone to HRT in patients 
with early stage EOC who protect their uterus after primary surgery [17].
With regard to duration, there is insufficient data on the effect of long or short 
term use of HRT on the onset or progression of ovarian cancer. A recent meta-
analysis conducted by Li et al. on 1448 patients who investigated the effect of 
postoperative HRT on the clinical outcome of patients treated for EOC revealed 
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that post-operative HRT did not have an impact on surveillance and recurrence 
(HR = 0.68, 95% CI: 0.54–0.86) [23].
Among the HRT users diagnosed with invasive EOC (n = 649) and borderline ovar-
ian tumors (BOT; n = 150), there was no difference in 5-year survival of invasive cancer 
patients among HRT users and non-users. However, survival was better for those with 
borderline tumors who used HRT after diagnosis [24]. In addition, tumor types classi-
fied as border type, including serous and mucinous tumors had a large heterogeneity. 
There have been recent studies showing that borderline serous tumors can progress to 
low-grade serous ovarian cancer. Low-grade serous cancers are considered hormone-
sensitive tumors, and therefore, it is important to avoid using HRT in patients with 
borderline serous tumors, although there is no definitive evidence to indicate this [25].
Evaluation of HRT after radical treatment of germ cell and cord ovarian malig-
nancies is very important, as most of the cases are in young, premenopausal women 
who may be subject to several reductions in estrogen levels. However, there are no 
trials evaluating the use of HRT in these patients. Although HRT can be used safely 
for many of the germ cell tumors, we believe that it should be used carefully in a 
small subgroup of germ cell tumors that may secrete hormones. In the cases, the 
treatment of menopausal symptoms with HRT should be avoided and alternatives 
should be investigated after diagnosis [26].
In the foreground affects postmenopausal women, the improvement of climac-
teric symptoms following ovarian cancer diagnosis is an important concern for 
young women. Meta-analysis of 6 studies comparing 451 ovarian cancer patients 
who were treated with HRT after the diagnosis compared with 1070 women treated 
with HRT for control; revealed that there was no statistically significant difference 
in survival results [27, 28].
Some observational studies in this patient population have shown a possible 
benefit, as there is no increase in the risk of recurrence with HRT [29].
When we look at the results of two studies, which are very valuable because 
being prospective and evaluate according to whether or not patients with ovarian 
cancer receive random HRT. One of these studies was conducted on 59 patients who 
were received HRT with only estrogen and 66 control patients who did not receive 
any treatment. All stages of ovarian cancer were included in the study and the mean 
follow-up period was 42 months. In the group receiving HRT, the disease-free inter-
val and OS were 34 and 44 months respectively, while in the non-treatment group, 
these durations were 27 and 34 months respectively, but the difference between the 
groups was not statistically significant [30].
For ovarian cancer, the available evidence suggests either a neutral effect on 
survival or a possible benefit from HRT. In view of the limitations of available evi-
dence, factors such as the age of the patient, the presence of menopausal symptoms, 
and the molecular and hormonal characteristics of the tumor affect the initiation of 
HRT in some histological types of ovarian cancer [31].
A number of problems could not be resolved. For example, what the best HRT 
regimens are for patients with ovarian cancer and how long patients should take 
HRT after surgery, as well as how the use of HRT affects the clinical outcomes of 
patients with previous EOC diagnoses, require further study. At present, we know 
that in ovarian cancer patients there is no published study confirming the growth of 
microscopic residues that are encouraged by the use of HRT.
4. Cervical cancer
The mean age of cervical cancer is 48 years, and when diagnosed 70% of 
patients are under 54 years of age. Depending on the patient’s age, the stage and 
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histology of the tumor, such patients are usually treated with radical hysterectomies 
without preserving the ovarian or chemo-radiation treatment, in which patients 
begin to have sudden menopausal symptoms [32].
Approximately 80% of cervical cancers are composed of squamous cell carcino-
mas (SCC), 15% are adenocarcinoma and 5% are adenosquamous. The development 
of squamous cell carcinomas has never been associated with HRT. In contrast, there 
are studies that report the risk of adenocarcinoma of the cervix as notable in women 
receiving estrogen therapy (OR 2.7) [33].
In 80 patients under 45 years of age with early-stage disease treated with surgery 
or radiotherapy, HRT was used, while the remaining 40 cervical cancer patients 
were used as controls. No significant difference in survival or survival was observed 
between the groups [34].
5. Conclusions
According to preclinical data, estrogen and progesterone are thought to play 
a role in the induction and progression of endometrial cancers. When the data 
is examined, epithelial ovarian cancer (EOC) appears to be at least partially 
hormonally affected. Considering the literature, the use of HRT is controversial 
in gynecologic cancer survivors. Given the fear of recurrence and the risk of 
developing ovarian or endometrial cancer most clinicians are reluctant to write 
HRT prescriptions for these patients but HRT does not appear to be associated 
with an increased risk of relapse in ovarian and endometrial cancer survivors, 
especially when used for a short period of time. In order to make an inference 
in terms of cervical cancer, squamous cell cancer is not associated with estrogen 
as mentioned above, but the risk of cervical adenocarcinoma increased signifi-
cantly in women receiving estrogen therapy. Prior to the decision to use HRT, it 
is imperative that a proper consultation is done to individualize treatment on the 
basis of potential risks and benefits, including close follow-ups. However, with 
strongly informed consent, we believe that physicians may consider writing a 
course of HRT treatment to minimize menopausal symptoms and illnesses related 
to hormonal reduction on an individual basis.
In conclusion, further studies are needed for the role of hormonal modulation 
in the development, treatment, and management of climacteric symptoms after 
diagnosis, despite the modern emphasis of precision medicine in cancer care. In 
the patient group diagnosed with gynecological cancer, it is necessary to better 
define the conditions in which HRT can provide benefit or harm. Although there 
are some pre-clinical and epidemiological evidence that contradicts individual 
experience, observational or small randomized studies, there are available data 
in the literature to advice women on general and specific risks and benefits of 
HRT. Given high discontinuation rates and low medical compliance, we still have 
much to do in terms of informing women about the advantages and disadvantages 
of HRT and encouraging the appropriate use of HRT. Finally, to the extent that 
we can get rid of progressive diseases such as cancer, we can achieve the expected 
successful healthy aging goal.
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